Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo.

Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire 03755, USA.
Diabetes (Impact Factor: 8.47). 10/2001; 50(9):2139-47. DOI: 10.2337/diabetes.50.9.2139
Source: PubMed

ABSTRACT Nonenzymatic glycation appears to be an important factor in the pathogenesis of diabetic complications. Key early intermediates in this process are fructosamines, such as protein-bound fructoselysines. In this report, we describe the purification and characterization of a mammalian fructosamine-3-kinase (FN3K), which phosphorylates fructoselysine (FL) residues on glycated proteins, to FL-3-phosphate (FL3P). This phosphorylation destabilizes the FL adduct and leads to its spontaneous decomposition, thereby reversing the nonenzymatic glycation process at an early stage. FN3K was purified to homogeneity from human erythrocytes and sequenced by means of electrospray tandem mass spectrometry. The protein thus identified is a 35-kDa monomer that appears to be expressed in all mammalian tissues. It has no significant homology to other known proteins and appears to be encoded by genomic sequences located on human chromosomes 1 and 17. The lability of FL3P, the high affinity of FN3K for FL, and the wide distribution of FN3K suggest that the function of this enzyme is deglycation of nonenzymatically glycated proteins. Because the condensation of glucose and lysine residues is an ubiquitous and unavoidable process in homeothermic organisms, a deglycation system mediated by FN3K may be an important factor in protecting cells from the deleterious effects of nonenzymatic glycation. Our sequence data of FN3K are in excellent agreement with a recent report on this enzyme by Delpierre et al. (Diabetes 49:1627-1634, 2000).

  • [Show abstract] [Hide abstract]
    ABSTRACT: Amadoriases are discovered in distant groups of organisms ranging from bacteria to humans. These enzymes catalyze the degradation of Amadori products which are formed in the early stage a non-enzymatic reaction between reducing sugars and primary amines called the Maillard reaction or glycation. The physiological role of amadoriases is debatable and perhaps not constrained to one cellular process only. Among other functions amadoriases are proposed to ensure enzymatic defense against the deleterious consequences of protein glycation. A decade ago an amadoriase enzyme (the FrlB amadoriase) has been discovered in Escherichia coli catalyzing the removal of Amadori products form the.-amino group of free lysine. The E. coli FrlB enzyme has been suggested to catabolize glycated lysine released in the human intestine upon digestion of food proteins. In the present study we demonstrate that the E. coli FrlB amadoriase is capable of catalyzing in the reverse reaction the formation of Amadori products on a number of free amino acids and on polypeptides as well. Based on these results we suggest that in the forward reaction the FrlB enzyme might serve to deglycate E. coli proteins thus helping bacterial cells to withstand the protein glycation burden.
    Biotechnology & Biotechnological Equipment 10/2011; 26. DOI:10.5504/50YRTIMB.2011.0026 · 0.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biological amines react with reducing sugars to form a heterogeneous group of compounds, called advanced glycation end products, a process known as the Maillard reaction. Glycation of proteins starts with formation of Shiff's base, which rearrange into Amadori product. The Amadori products then undergo a series of chemical modifications to form advanced glycation end products (AGEs). Many advanced glycation end products are capable of forming cross-links between proteins and many of them are fluorophores. The formation of AGEs is an irreversible process and glycation is a major cause of spontaneous damage to proteins in physiological systems. AGEs accumulate in tissues with age and their rate of accumulation is accelerated in diabetes. Hyperglycemia in diabetes causes accelerated AGEs formation and has been linked to various diabetic complications like nephropathy, retinopathy, angiopathy, and neuropathy. Nature has several defense mechanisms to protect tissues from AGEs accumulation. Among them are amadoriases, which can remove the Amadori product and interrupt the glycation cascade in the early steps of the Maillard reaction. To date three classes of deglycating enzymes were found-fructosamine oxidases, fructosamine-3-kinases, and fructoselysine 6-phosphate deglycase. These enzymes are known to occur in mammalian, fungal and other eukaryotic and prokaryotic cells.
    Biotechnology & Biotechnological Equipment 03/2010; 24(3). DOI:10.2478/V10133-010-0066-7 · 0.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Glycation is a non-enzymatic reaction of protein amino and guanidino groups with reducing sugars or dicarbonyl products of their oxidative degradation. Modification of arginine residues by dicarbonyls such as glyoxal and methylglyoxal results in formation of advanced glycation end-products (AGEs). In mammals, these modifications impact in diabetes mellitus, uremia, atherosclerosis and ageing. However, due to the low abundance of individual AGE-peptides in enzymatic digests, these species cannot be efficiently detected by LC-ESI-MS-based data-dependent acquisition (DDA) experiments. Here we report an analytical workflow that overcomes this limitation. We describe fragmentation patterns of synthetic AGE-peptides and assignment of modification-specific signals required for unambiguous structure retrieval. Most intense signals were those corresponding to unique fragment ions with m/z 152.1 and 166.1, observed in the tandem mass spectra of peptides, containing glyoxal- and methylglyoxal-derived hydroimidazolone AGEs, respectively. To detect such peptides, specific and sensitive precursor ion scanning methods were established for these signals. Further, these precursor ion scans were incorporated in conventional bottom-up proteomic approach based on data-dependent acquisition (DDA) LC-MS/MS experiments. The method was successfully applied for the analysis of human serum albumin (HSA) and human plasma protein tryptic digest with subsequent structure confirmation by targeted LC-MS/MS (DDA). Altogether 44 hydroimidazolone- and dihydroxyimidazolidine-derived peptides representing 42 AGE-modified proteins were identified in plasma digests obtained from type 2 diabetes mellitus (T2DM) patients. Copyright © 2015 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd.
    Journal of Mass Spectrometry 03/2015; 50(3). DOI:10.1002/jms.3569 · 2.71 Impact Factor